CMS’ Medicare ne­go­ti­a­tion list is com­ing next week. Here’s what to ex­pect

Last year
Pharma
FDA+

CA fed­er­al judge al­lows for­mer em­ploy­ee's case against So­ma­Log­ic to con­tin­ue

Last year
Pharma
Law

CVS Health goes in­to the biosim­i­lar mar­ket with new sub­sidiary

Last year
Pharma
Manufacturing

Man­u­fac­tur­ing roundup: Ther­mo Fish­er named con­tract man­u­fac­tur­er for We­govy; Fu­ji­film Diosynth ex­pands its busi­ness ...

Last year
Manufacturing

Af­ter first-line ap­proval in DL­B­CL, de­bate con­tin­ues around ben­e­fit from Roche's ADC Po­livy

Last year
R&D

Cel­lares rais­es $255M as it boosts its own man­u­fac­tur­ing ef­forts

Last year
Financing
Manufacturing

Ake­bia ex­pects to file vadadu­s­tat again to FDA by end of Q3; So­ci­etal CD­MO seeks to se­cure 8M+ in lat­est raise

Last year
News Briefing

Ab­b­Vie drops two ear­ly-stage AD­Cs, in­clud­ing Pfiz­er-part­nered on­col­o­gy pro­gram

Last year
R&D
Pharma

SPAC merg­er falls through be­tween Wilbur Ross' blank check com­pa­ny and Alzheimer's play­er

Last year
Deals

KRAS late­com­er Roche draws cau­tious com­par­isons to Am­gen, Mi­rati in ear­ly da­ta

Last year
R&D

Roy­al­ty Phar­ma pays Fer­ring $300M for 5% roy­al­ty on sales of can­cer gene ther­a­py Ad­sti­ladrin

Last year
Deals

In PhI­II da­ta, Eli Lil­ly’s Retev­mo meets pri­ma­ry end­point of im­prov­ing pro­gres­sion-free sur­vival

Last year
R&D
Pharma

FDA ad­vi­so­ry com­mit­tee will meet next month to dis­cuss Intar­ci­a's di­a­betes drug

Last year
Pharma
FDA+

Mallinck­rodt signs re­struc­ture agree­ment with cred­i­tors, plans to file for bank­rupt­cy

Last year
Pharma

Bris­tol My­ers touts ear­ly so­cial and en­vi­ron­men­tal progress among achieve­ments in lat­est ESG re­port

Last year
Pharma
Marketing

GSK asks US patent of­fice to refuse Mod­er­na’s ‘Covid Mvax’ trade­mark reg­is­tra­tion as 'too gener­ic'

Last year
Pharma
Marketing

Biden awards $24M to de­vel­op mR­NA tech tar­get­ing can­cer, oth­er dis­eases

Last year
R&D
Pharma

Ipsen gives back Parkin­son’s drug af­ter fail­ing PhI­Ib study; Par­a­digm Ther­a­peu­tics gets glob­al rights to skin ...

Last year
News Briefing

J&J to close its Lei­den vac­cine unit fol­low­ing wider in­fec­tious dis­ease cuts

Last year
R&D

Agenus to trim its staff num­bers and as­sets

Last year
People
R&D

Pfiz­er ex­pects few­er peo­ple need­ed for Ly­me dis­ease vac­cine tri­al

Last year
R&D
Pharma

No­var­tis to cut 103 clin­i­cal work­ers in New Jer­sey

Last year
People

Fore scores $75M Se­ries D, tees up new lead­er­ship with ex-El­e­va­tion CEO Shawn Le­land at the helm — for now

Last year
Financing
Startups

Roche posts in­ter­im OS da­ta from PhI­II TIG­IT tri­al af­ter leak — and an­a­lysts say it bodes well for fi­nal read­out

Last year
R&D
First page Previous page 291292293294295296297 Next page Last page
A service from the Financial Times